Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells

Molecular Pharmaceutics

Volumn 11, Issue 6, 2014, Pages 1897-1905

  K c , Remant Bahadur ^a   Chandrashekaran, Varun ^a   Cheng, Bei ^a   Chen, Hexin ^a   Peña, Maria Marjorette O ^a   Zhang, Jiajia ^a   Montgomery, Janis ^b   Xu, Peisheng ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b South Carolina Oncology Associates   (United States)

Author keywords

camptothecin; drug delivery; HER2 positive; polymer drug conjugate; redox sensitive

Indexed keywords

CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MACROGOL; NANOPARTICLE; TRASTUZUMAB; DOXORUBICIN; ERBB2 PROTEIN, HUMAN; MACROGOL DERIVATIVE; POLYMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOFABRICATION; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; BREAST NEOPLASMS; CHEMISTRY; FEMALE; GENETICS; HCT116 CELL LINE; KB CELL LINE; OXIDATION REDUCTION REACTION; PROCEDURES; TUMOR CELL LINE;

BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HCT116 CELLS; HUMANS; KB CELLS; NANOPARTICLES; OXIDATION-REDUCTION; POLYETHYLENE GLYCOLS; POLYMERS; RECEPTOR, ERBB-2;

EID: 84901808285     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5000482     Document Type: Article

References (39)

1. Master, A. M.; Rodriguez, M. E.; Kenney, M. E.; Oleinick, N. L.; Gupta, A. S. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies J. Pharm. Sci. 2010, 99 (5) 2386-2398
2. Xu, P.; Van Kirk, E. A.; Murdoch, W. J.; Zhan, Y.; Isaak, D. D.; Radosz, M.; Shen, Y. Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles Biomacromolecules 2006, 7 (3) 829-835
3. Immordino, M. L.; Dosio, F.; Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 2006, 1 (3) 297-315
4. Moreira, J. N.; Gaspar, R.; Allen, T. M. Targeting stealth liposomes in a murine model of human small cell lung cancer Biochim. Biophys. Acta 2001, 1515 (2) 167-176
5. Shi, M.; Ho, K.; Keating, A.; Shoichet, M. S. Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery Adv. Funct. Mater. 2009, 19 (11) 1689-1696
6. Zhou, Z.; Shen, Y.; Tang, J.; Fan, M.; Van Kirk, E. A.; Murdoch, W. J.; Radosz, M. Charge-Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery Adv. Funct. Mater. 2009, 19 (22) 3580-3589
7. Guo, R.; Shi, X. Dendrimers in cancer therapeutics and diagnosis Curr. Drug Metab. 2012, 13 (8) 1097-1109
8. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications Drug Discovery Today 2010, 15 (5-6) 171-185
9. Sun, T.-M.; Wang, Y.-C.; Wang, F.; Du, J.-Z.; Mao, C.-Q.; Sun, C.-Y.; Tang, R.-Z.; Liu, Y.; Zhu, J.; Zhu, Y.-H.; Yang, X.-Z.; Wang, J. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds Biomaterials 2014, 35 (2) 836-845
10. Shen, J.; Song, G.; An, M.; Li, X.; Wu, N.; Ruan, K.; Hu, J.; Hu, R. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy Biomaterials 2014, 35 (1) 316-326
11. Xu, P.; Van Kirk, E. A.; Zhan, Y.; Murdoch, W. J.; Radosz, M.; Shen, Y. Targeted charge-reversal nanoparticles for nuclear drug delivery Angew. Chem., Int. Ed. 2007, 46 (26) 4999-5002
12. Furgeson, D. Y.; Dreher, M. R.; Chilkoti, A. Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors J. Controlled Release 2006, 110 (2) 362-369
13. Karavelidis, V.; Karavas, E.; Giliopoulos, D.; Papadimitriou, S.; Bikiaris, D. Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior Int. J. Nanomed. 2011, 6, 3021-3032
14. Mohammadi, G.; Valizadeh, H.; Barzegar-Jalali, M.; Lotfipour, F.; Adibkia, K.; Milani, M.; Azhdarzadeh, M.; Kiafar, F.; Nokhodchi, A. Development of azithromycin-PLGA nanoparticles: Physicochemical characterization and antibacterial effect against Salmonella typhi Colloids Surf., B 2010, 80 (1) 34-39
15. Owens, D. E., III; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 2006, 307 (1) 93-102
16. Zhou, Z. X.; Shen, Y. Q.; Tang, J. B.; Fan, M. H.; Van Kirk, E. A.; Murdoch, W. J.; Radosz, M. Charge-Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery Adv. Funct. Mater. 2009, 19 (22) 3580-3589
17. Xu, P.; Tang, H.; Li, S.; Ren, J.; Van Kirk, E.; Murdoch, W. J.; Radosz, M.; Shen, Y. Enhanced stability of core-surface cross-linked micelles fabricated from amphiphilic brush copolymers Biomacromolecules 2004, 5 (5) 1736-1744
18. K.C., R. B.; Thapa, B.; Xu, P. pH and redox dual responsive nanoparticle for nuclear targeted drug delivery Mol. Pharmaceutics 2012, 9 (9) 2719-2729
19. Gauthier, M. A.; Gibson, M. I.; Klok, H. A. Synthesis of functional polymers by post-polymerization modification Angew. Chem., Int. Ed. 2009, 48 (1) 48-58
20. K.C., R. B.; Xu, P. Multicompartment Intracellular Self-Expanding Nanogel for Targeted Delivery of Drug Cocktail Adv. Mater. 2012, 24 (48) 6479-6483
21. Shen, Y.; Zhou, Z.; Sui, M.; Tang, J.; Xu, P.; Van Kirk, E. A.; Murdoch, W. J.; Fan, M.; Radosz, M. Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery Nanomedicine (London, U.K.) 2010, 5 (8) 1205-1217
22. Demeule, B.; Palais, C.; Machaidze, G.; Gurny, R.; Arvinte, T. New methods allowing the detection of protein aggregates: A case study on trastuzumab mAbs 2009, 1 (2) 142-150
23. Xiao, K.; Li, Y.; Luo, J.; Lee, J. S.; Xiao, W.; Gonik, A. M.; Agarwal, R. G.; Lam, K. S. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles Biomaterials 2011, 32 (13) 3435-3446
24. Schafer, F. Q.; Buettner, G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple Free Radical Biol. Med. 2001, 30 (11) 1191-1212
25. Pradeep, C. R.; Zeisel, A.; Kostler, W. J.; Lauriola, M.; Jacob-Hirsch, J.; Haibe-Kains, B.; Amariglio, N.; Ben-Chetrit, N.; Emde, A.; Solomonov, I.; Neufeld, G.; Piccart, M.; Sagi, I.; Sotiriou, C.; Rechavi, G.; Domany, E.; Desmedt, C.; Yarden, Y. Modeling invasive breast cancer: Growth factors propel progression of HER2-positive premalignant lesions Oncogene 2012, 31 (31) 3569-3583
26. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery J. Controlled Release 2008, 126 (3) 187-204
27. Meng, F. H.; Hennink, W. E.; Zhong, Z. Reduction-sensitive polymers and bioconjugates for biomedical applications Biomaterials 2009, 30 (12) 2180-2198
28. Bae, Y.; Fukushima, S.; Harada, A.; Kataoka, K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change Angew. Chem., Int. Ed. 2003, 42 (38) 4640-4643
29. Pan, Y.-J.; Chen, Y.-Y.; Wang, D.-R.; Wei, C.; Guo, J.; Lu, D.-R.; Chu, C.-C.; Wang, C.-C. Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release Biomaterials 2012, 33 (27) 6570-6579
30. Luo, Z.; Cai, K.; Hu, Y.; Zhao, L.; Liu, P.; Duan, L.; Yang, W. Mesoporous Silica Nanoparticles End-Capped with Collagen: Redox-Responsive Nanoreservoirs for Targeted Drug Delivery Angew. Chem., Int. Ed. 2011, 50 (3) 640-643
31. Gusterson, B. A.; Gelber, R. D.; Goldhirsch, A.; Price, K. N.; Save-Soderborgh, J.; Anbazhagan, R.; Styles, J.; Rudenstam, C. M.; Golouh, R.; Reed, R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J. Clin. Oncol. 1992, 10 (7) 1049-1056
32. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989, 244 (4905) 707-712
33. Shepard, H. M.; Jin, P.; Slamon, D. J.; Pirot, Z.; Maneval, D. C. Herceptin Handb. Exp. Pharmacol. 2008, 181, 183-219
34. Yan, L.; Ehrlich, P. J.; Gibson, R.; Pickett, C.; Beckman, R. A. How can we improve antibody-based cancer therapy? mAbs 2009, 1 (1) 67-70
35. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 2002, 20 (3) 719-726
36. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 N. Engl. J. Med. 2001, 344 (11) 783-792
37. Diermeier, S.; Horvath, G.; Knuechel-Clarke, R.; Hofstaedter, F.; Szollosi, J.; Brockhoff, G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation Exp. Cell Res. 2005, 304 (2) 604-619
38. Ritter, C. A.; Perez-Torres, M.; Rinehart, C.; Guix, M.; Dugger, T.; Engelman, J. A.; Arteaga, C. L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin. Cancer Res. 2007, 13 (16) 4909-4919
39. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53 (1) 615-627